Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs inc... PRTA - Prothena Corporation plc Income Statement Quarterly Quarterly | Annual Earnings Estimates: Analyst Consensus: Analyst Trends: Margins and Revenue: Debt & Cash Analysis: Expense Analysis: Cashflow Analysis: More